| Symbol | EIKN |
|---|---|
| Name | EIKON THERAPEUTICS, INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | Biological Products, (No Diagnostic Substances) |
| Address | 230 HARRIET TUBMAN WAY, MILLBRAE, California, 94030, United States |
| Telephone | +1 341 777-0566 |
| Fax | — |
| — | |
| Website | https://www.eikontx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001861123 |
| Description | We are data scientists and chemists, biologists and engineers, clinicians and lab managers, pharmacologists and software developers. We work across functions and employ diverse scientific languages. We work with super-resolution microscopes, living cells, algorithms, and robotics - all so we can observe therapeutically relevant biology in a way no one has before. We are endlessly curious, intellectually honest and we love what we do. We are driven to explore mechanisms of biology and pharmacology at the molecular level, and to make the biggest difference in as many lives as possible. Additional info from NASDAQ: |
Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer
Read moreEikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress
Read more(99% Neutral) EIKON THERAPEUTICS, INC. (EIKN) Announces New Board Appointment
Read moreEikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology
Read moreEikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology
Read moreNew Form SCHEDULE 13G - Eikon Therapeutics, Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001720215-26-000006 <b>Size:</b> 20 KB
Read moreNew Form SCHEDULE 13G - Eikon Therapeutics, Inc. <b>Filed:</b> 2026-05-13 <b>AccNo:</b> 0001193125-26-221988 <b>Size:</b> 6 KB
Read more(85% Positive) EIKON THERAPEUTICS, INC. (EIKN) Announces Enrollment Update for Conference Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment
Read moreEikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates
Read more